Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$23.33
-0.49 (-2.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $120.1M · quality 77.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.8B
P/E
18.4x
↓EV/EBITDA
12.7x
↑ROE
19.0%
↑Gross Margin
65.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.8%
FCF CAGR
+12.1%
FCF margin
20.3%
FCF / Net income
0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $525.3M · net income $207.5M · FCF $106.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $525.3M | $525.3M | $474.6M | $471.9M | $456.9M |
| Net Income | $207.5M | $207.5M | $205.3M | $203.6M | $175.2M |
| EBITDA | $243.9M | $243.9M | $242.3M | $240.4M | $209.8M |
| EPS | 1.29 | 1.29 | 1.53 | 1.70 | 1.46 |
| Gross Margin | 65.0% | 65.0% | 65.6% | 65.5% | 59.0% |
| Operating Margin | 45.8% | 45.8% | 49.3% | 49.3% | 44.7% |
| Net Margin | 39.5% | 39.5% | 43.3% | 43.2% | 38.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 7.97 | 7.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $106.6M | $106.6M | $128.3M | $120.1M | $75.6M |
| Returns | |||||
| ROE | 19.0% | 19.0% | 16.6% | 35.1% | 47.0% |
| Valuation | |||||
| P/E | 18.37 | 18.37 | 19.51 | — | — |
| EV/EBITDA | 12.74 | 12.74 | 12.89 | — | — |
| P/B | 3.43 | 3.43 | 3.24 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 10.7% | 10.7% | 0.6% | 3.3% | — |
| EPS Growth | -15.7% | -15.7% | -10.0% | 16.4% | — |
| Dividend Yield | 9.2% | 9.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
17.1%
EPS terminal req.
$2.07
Spread vs growth
-32.8%
5Y implied EPS CAGR
14.2%
EPS terminal req.
$2.50
Spread vs growth
-29.9%
10Y implied EPS CAGR
12.1%
EPS terminal req.
$4.03
Spread vs growth
-27.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.6%
Start / end P/E
19.0x → 18.1x
EPS bridge
1.53 → 1.29
Residual
+0.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.